What Is Remission for Acute Myeloid Leukemia?

In the context of acute myeloid leukaemia (AML), remission refers to the complete disappearance of all detectable leukaemia cells in the bone marrow and blood, as well as the resolution of any associated symptoms. It is an essential milestone in the treatment of AML, as it marks the point at which the disease is no longer actively progressing.

Complete remission (CR) is defined as the absence of any blasts or leukaemia cells in the bone marrow and peripheral blood, and the restoration of normal hematopoiesis (blood cell production). This assessment is based on a thorough examination of the bone marrow, including cytology and flow cytometry, as well as blood counts and other relevant tests.

The achievement of remission in AML is crucial, as it significantly improves the prognosis and overall survival of patients. It allows for further treatment options, such as hematopoietic stem cell transplantation (HSCT), which can potentially cure the disease. However, it is important to note that remission does not equate to a cure, as the risk of relapse remains. Regular monitoring and follow-up care are necessary to detect and manage any signs of recurrence.